Metrics as of 10/14/2026, 02:33 PM (Berlin time), refresh in progress.
Mesoblast Stock
Mesoblast Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- CEO
- Silviu Itescu
- Employees
- 108
- Market cap
- $1.8 B
- IPO
- 20/01/2010
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Established in 2004, the company is headquartered in Melbourne, Australia, and employs 108 employees. Its global presence extends across the United States, Australia, Singapore, the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Mesoblast stock: price history
1D
-2.6%
1W
+2.1%
1M
-10.2%
6M
-4.9%
YTD
-22.9%
1Y
-23.4%
2Y
+37.9%
5Y
+22.8%
10Y
+60.9%
Next earnings date
Next earnings date
04/03/2027 (in 138 days)
Volatility around earnings
~28% weaker price swings than usual
Ask the agents about Mesoblast
Analyst assessment of Mesoblast
PRICE TARGET LOW
US$39.00
CONSENSUS
US$39.00
MEDIAN
US$39.00
PRICE TARGET HIGH
US$39.00
0
STRONG BUY
5
BUY
4
HOLD
2
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 27/08/2026
Mesoblast stock metrics
P/E
-31.29
P/B
3.17
EV/EBITDA
-42.19
RETURN ON EQUITY
-1.5%
NET MARGIN
-25.2%
DEBT/EQUITY
0.22
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.5%
FLOAT SHARES
83,676,161
AVG. DAILY VOLUME (30D)
211,467
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Mesoblast stock
What does Mesoblast do?
Mesoblast Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in Australia.
The CEO is Silviu Itescu, the company employs around 108 people.
The IPO was on 20/01/2010; the stock trades on NASDAQ under the ticker MESO.
What do analysts say about Mesoblast stock?
11 analysts rate the stock, the consensus is Buy (as of 27/08/2026).
The average price target is US$39.00, ranging from US$39.00 to US$39.00, with a median of US$39.00.
This is an external assessment, not a statement by Market Jury.
When does Mesoblast report next?
The next earnings date is 04/03/2027.
Around past earnings, price swings were roughly -28% stronger than usual.
Does Mesoblast pay a dividend?
No, Mesoblast currently does not pay a dividend.
Which stocks are comparable to Mesoblast?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Mesoblast stock analyzed?
Clicking "Analyze stock" lets five strategies assess Mesoblast against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.